Formulary guidance and transparency from P&T to point of care

MMIT Reality Check on Alpha-1 Antitrypsin Deficiency (Dec 2018)

Posted by Matt Breese on Dec 21, 2018

Find me on:

According to our recent payer coverage analysis for alpha-1 antitrypsin deficiency treatments, combined with news from key healthcare influencers, market access is shifting in this drug landscape.

To help make sense of this new research, MMIT's team of experts analyzes the data and summarizes the key findings for you. The following are brief highlights. To read the full piece, including payer coverage, drug competition and prescriber trends, click here.

Payer Coverage: A review of market access for alpha-1 antitrypsin deficiency treatments shows that among the four medications covered under the medical benefit, only 16% of the lives have utilization management restrictions under Medicare policies.

MMIT-Reality Check-AATD_4Q2018Data snapshot as of Q4 2018

Trends: The FDA allowed marketing of 23and Me, Inc's Personal Genome Service Genetic Health Risk tests in 2017. The tests look for generic variants in a person's saliva whose presence or absence can indicate a heightened risk for 10 conditions, including alpha-1 antitrypsin deficiency.

To read the full Reality Check on Alpha-1 Antitrypsin Deficiency treatments with key findings on clinical characteristics, drug market access and payer coverage, please click on the button below: 


View Reality Check

Topics: Specialty, Market Access, Payer, Branding & Marketing